- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03700749
FALCON Trial Testing Measures to Reduce Surgical Site Infection (FALCON)
Pragmatic Multicentre FActorial Randomised Controlled triaL Testing Measures to reduCe Surgical Site Infection in lOw and Middle Income couNtries
FALCON is a Pragmatic multi-centre trial testing measures to reduce superficial or deep skin infection following abdominal surgery in low and middle income countries. The trial will recruit patients undergoing abdominal surgery. Recruited participants will be randomly assigned to four arms to receive different combinations of skin preparation and sutures for would closure:
A. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and non-coated suture for wound closure; B. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and triclosan coated suture for wound closure; C. In this arm surgeon will use for operation 10% aqueous povidone-iodine for skin cleansing and non-coated suture for wound closure; D. In this arm surgeon will use 10% aqueous povidone-iodine for skin cleansing and triclosan-coated suture.
Study Overview
Status
Conditions
Detailed Description
FALCON is a pragmatic, blinded (patient and outcome assessor), 2x2 factorial, stratified, multi-centre randomised controlled trial, with an internal pilot, to evaluate measures to reduce Surgical Site Infection (SSI) rates in patients undergoing surgery with an abdominal incision.
Surgical site infection (SSI) represents a major burden for patients, doctors, and health systems across all settings. SSI is the commonest postoperative complication worldwide and the commonest healthcare-associated infection in low and middle income countries (LMICs). SSIs cause pain, discomfort, disability, and increase the time taken to return to work (3). SSIs increase healthcare costs in all health settings. Whilst there is no direct data on the costs of SSI in LMICs, within the UK National Health Service, SSIs cost approximately £3500 per patient and £700 million per year in total. The impact of increased healthcare costs on patients, communities, and providers can be major in LMICs where personal income is low and patients may be required to pay for their own treatment. SSI has also been associated with one-third of postoperative deaths and accounts for 8% of all deaths caused by a hospital acquired infection.
Strata in FALCON trial are defined according to the anticipated category of wound contamination: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between:
A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture.
Participant will be recruited from hospitals in Low and Middle Income Countries (LMICs). Participants who is undergoing abdominal surgery with an anticipated clean-contaminated, contaminated or dirty surgical wound will be selected to enter the trial.
The 6 month internal pilot will assess the feasibility of recruitment, compliance with treatment allocation and patient retention and follow-up rates. The main RCT will recruit 5480 participants.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Tina Griffin, BMedSc
- Phone Number: 0121 414 4762
- Email: falcon@trials.bham.ac.uk
Study Contact Backup
- Name: Rachel Lillywhite, BA
- Phone Number: 0121 414 4762
- Email: GlobalSurg@trials.bham.ac.uk
Study Locations
-
-
-
Lagos, Nigeria
- Recruiting
- Lagos University Teaching Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with at least one abdominal incision that is ≥5cm (open or laparoscopic extraction site), with an anticipated clean-contaminated, contaminated or dirty surgical wound.
- Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) operations.
- Any operative indication, including trauma surgery.
- Patient able and willing to provide written informed consent (signature or a fingerprint).
- Paediatric and adult patients. This criteria is made country-specific. Each country decides the lower age limit for the trial. This is dependent on country-specific regulatory approvals. Age eligibility will vary by country.
Exclusion Criteria:
- Patients with a documented or suspected allergy to iodine, shellfish, or chlorhexidine skin preparation solution.
- Patient unable to complete post-operative follow-up (i.e. will not be contactable after discharge).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2%chlorhexidine + non-coated suture
2%alcoholic chlorhexidine + non-coated suture.
Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
|
Interventions: 2% alcoholic chlorhexidine non-coated suture |
Active Comparator: 2%chlorhexidine + coated suture
2%alcoholic chlorhexidine + triclosan-coated suture.
Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
|
Interventions: 2% alcoholic chlorhexidine triclosan coated suture |
Active Comparator: 10% povidone-iodine + non-coated suture
10% povidone-iodine and non-coated suture.
Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
|
Interventions: 10% povidone-iodine non-coated suture non-coated suture |
Active Comparator: 10%povidone-iodine + coated suture
10%povidone-iodine/triclosan-coated suture.
Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
|
Interventions: 10% povidone-iodine triclosan coated suture |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical site infection (SSI)
Time Frame: At 30-days post-surgery
|
Deep incisional or superficial incisional SSI which must occur within 30 days of the index operation.
The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision.
Patient must at least have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.
|
At 30-days post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physiological parameter - SSI at discharge from hospital
Time Frame: Within 30-days post surgery from index operation
|
Deep incisional or superficial incisional SSI.
The infection must involve the skin, subcutaneous, muscular or fascial layers of the incision and the patient must have one of the following: (1) purulent discharge from wound; (2) organisms detected from wound swab; (3) Wound opened spontaneously or by a clinician AND, at the surgical wound, the patient has at least one of: pain or tenderness; localised swelling; redness; heat; systemic fever (>38°C); (4) Diagnosis of SSI by a clinician or on imaging.
|
Within 30-days post surgery from index operation
|
Mortality - patient mortality status
Time Frame: Within 30-days post surgery from index operation
|
Mortality within 30-days post surgery
|
Within 30-days post surgery from index operation
|
Physiological parameter - Unplanned wound opening
Time Frame: Within 30-days post surgery from index operation
|
Whether an unplanned wound opening has occurred at abdominal surgical site within 30-days post surgery, spontaneously opened or by clinician
|
Within 30-days post surgery from index operation
|
Re-operation for SSI
Time Frame: Within 30-days post surgery from index operation
|
Re-operation for SSI within 30-days post surgery
|
Within 30-days post surgery from index operation
|
Length of hospital stay for index admission
Time Frame: Within 30-days post surgery from index operation
|
Length of hospital stay for index admission will be collected and will measure time from surgery to time of discharge.
|
Within 30-days post surgery from index operation
|
Participant's Readmission
Time Frame: Within 30-days post surgery from index operation
|
Whether patient readmitted within 30-days post surgery
|
Within 30-days post surgery from index operation
|
Questionnaire - return to normal activities
Time Frame: Within 30-days post surgery from index operation
|
Return to normal activities (e.g.
work, school, or family duties) ascertained by trial specific questionnaire
|
Within 30-days post surgery from index operation
|
Resistance of organisms
Time Frame: Within 30-days post surgery from index operation
|
Resistance of organisms detected from wound swabs to prophylactic antibiotics administered within 1 hour of incision
|
Within 30-days post surgery from index operation
|
Questionnaire - Health resource usage
Time Frame: Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.
|
Health resource usage within 30-days post surgery ascertained by trial specific questionnaire
|
Within 30-days post surgery. Health resource usage will only be collected for adult patients (aged 18 and above) at pre-selected centres. This will include costs of post-operative visits to various healthcare professionals.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dion Morton, University of Birmingham
Publications and helpful links
General Publications
- NIHR Global Research Health Unit on Global Surgery. Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-income countries. Lancet. 2022 Nov 19;400(10365):1767-1776. doi: 10.1016/S0140-6736(22)01884-0. Epub 2022 Oct 31.
- NIHR Global Research Health Unit on Global Surgery. Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial. Lancet. 2021 Nov 6;398(10312):1687-1699. doi: 10.1016/S0140-6736(21)01548-8. Epub 2021 Oct 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Disease Attributes
- Wound Infection
- Infections
- Communicable Diseases
- Surgical Wound Infection
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Dermatologic Agents
- Trace Elements
- Micronutrients
- Disinfectants
- Plasma Substitutes
- Blood Substitutes
- Iodine
- Cadexomer iodine
- Chlorhexidine
- Povidone-Iodine
- Povidone
- Chlorhexidine gluconate
Other Study ID Numbers
- RG_17-126
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Surgery
-
University Hospital MuensterCompletedAbdominal Surgery | Abdominothoracic SurgeryGermany
-
3MRecruitingAbdominal Surgery | Orthopedic Surgery | Vascular Surgery | Cardiovascular SurgeryUnited States
-
York Teaching Hospitals NHS Foundation TrustCompletedColorectal Surgery | Major Abdominal SurgeryUnited Kingdom
-
Technische Universität DresdenRecruiting
-
The Cleveland ClinicRecruiting
-
Washington University School of MedicineTerminatedAbdominal SurgeryUnited States
-
Sameh FathyCompleted
-
Universidade Federal de Santa MariaCompleted
-
The Cleveland ClinicWithdrawnAbdominal Surgery
-
Bayside HealthNational Health and Medical Research Council, AustraliaCompletedAbdominal SurgeryAustralia
Clinical Trials on 2% chlorhexidine + non-coated suture
-
University of Southern CaliforniaNot yet recruitingEmergency General Surgery | Trauma Abdomen | Laparotomy | Surgical Site Infections | Dehiscence WoundUnited States
-
Ana María García de la FuenteNot yet recruitingSurgical Site Infection | Periodontal Inflammation | Post-Surgical ComplicationSpain
-
The Affiliated Hospital of Qingdao UniversityRecruitingSuture, ComplicationChina
-
University of CatanzaroUnknownPeripheral Vascular Disease
-
West Virginia UniversityRecruitingEsophageal Cancer | Dysphagia, EsophagealUnited States
-
Temple UniversityWithdrawnLacerations | Injuries | WoundsUnited States
-
Ain Shams UniversityCompleted
-
University of California, DavisCompletedMelanoma | Basal Cell Carcinoma | Squamous Cell CarcinomaUnited States
-
Hospital General Universitario ElcheCompletedSurgical Site InfectionSpain
-
CES UniversityCompletedGynecologic Surgical ProceduresColombia